LBRX
LB Pharmaceuticals Inc
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
34.26
▼ 0.36 (1.04%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
34.62
Day high
35.59
Day low
33.73
Volume
432.76K
Market cap
$1.11B
P/E (TTM)
342.60
52W range
14.32 – 50.16
Trailing performance
Returnvs SPY
1W
-8.10%
-10.0%
1M
-30.56%
-31.7%
3M
+0.26%
-4.3%
6M
+35.42%
+17.2%
YTD
+53.91%
+39.7%
1Y
+127.64%
+111.2%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LBRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
77.42K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 12, 25 | NUSSBAUM RAN Director |
— | 411.68K | — | Indirect |
| Sep 12, 25 | PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. Beneficial Owner of more than 10% of a Class of Security |
— | 411.68K | — | Indirect |
| Sep 12, 25 | VIDA VENTURES GP III, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
— | 548.91K | — | Indirect |
| Sep 12, 25 | DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD Beneficial Owner of more than 10% of a Class of Security |
— | 686.14K | — | Indirect |
| Sep 12, 25 | NUSSBAUM RAN Director |
BUY | 1.00M | $15.00M | Indirect |
| Sep 12, 25 | PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.00M | $15.00M | Indirect |
| Sep 12, 25 | VIDA VENTURES GP III, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 333.33K | $5.00M | Indirect |
| Sep 12, 25 | DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.67M | $40.00M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
NUSSBAUM RAN |
Director | — | Conversion of Exercise of derivative security |
PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
VIDA VENTURES GP III, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.11B
Enterprise value$782.63M
Revenue (TTM)—
Gross profit—
EBITDA$-91.03M
Net income$-85.69M
EPS (TTM)$0.10
Free cash flow$-53.92M
Total cash$327.79M
Total debt$5.22M
Book value / share$11.59
Shares outstanding32.26M
Float26.46M
Short % of float20.49%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E342.60
Forward P/E-6.62
PEG ratio—
Price / sales—
Price / book2.96
EV / revenue—
EV / EBITDA-8.60
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-50.00%
Return on assets-29.98%
Debt / equity1.57
Current ratio15.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $16.74M | $51.17M | $7.84M | $1.35M | -67.3% |
| Selling, general & admin | $13.66M | $13.66M | $3.53M | $1.46M | +0.0% |
| Total operating expense | $30.40M | $64.83M | $11.38M | $2.81M | -53.1% |
| Operating income | -$30.40M | -$64.83M | -$11.38M | -$2.81M | +53.1% |
| Net interest income | $3.92M | $1.72M | -$4.01M | -$2.08M | +127.8% |
| Pre-tax income | -$25.20M | -$63.10M | -$6.27M | -$14.35M | +60.1% |
| Tax provision | $1.00K | $1.00K | $1.00K | $1.00K | 0.0% |
| Net income | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Net income to common | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Basic EPS | -3.13 | -17.82 | -1.77 | -4.05 | +82.4% |
| Diluted EPS | -3.13 | -17.82 | -1.77 | -4.05 | +82.4% |
| EBIT | -$30.40M | -$64.83M | -$1.45M | -$12.20M | +53.1% |
| EBITDA | -$30.08M | -$64.74M | -$1.45M | -$12.19M | +53.5% |
| Basic shares | 8.05M | 3.54M | 3.54M | 3.54M | +127.2% |
| Diluted shares | 8.05M | 22.44M | 22.44M | 22.44M | -64.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $250.17M | $22.98M | $14.98M | $21.40M | +988.8% |
| Cash & short-term investments | $295.21M | $28.00M | $43.29M | $21.40M | +954.4% |
| Total current assets | $308.43M | $28.88M | $45.63M | $21.49M | +968.0% |
| Property, plant & equipment | $3.73M | $4.16M | $23.00K | $3.00K | -10.2% |
| Total assets | $312.93M | $33.53M | $45.66M | $21.49M | +833.2% |
| Total current liabilities | $7.44M | $8.11M | $2.61M | $469.00K | -8.2% |
| Long-term debt | — | — | — | $24.15M | — |
| Total debt | $3.57M | $3.70M | $0 | $24.15M | -3.6% |
| Total liabilities | $11.62M | $128.09M | $80.13M | $50.30M | -90.9% |
| Retained earnings | -$129.53M | -$104.32M | -$41.22M | -$34.95M | -24.2% |
| Shareholder equity | $301.31M | -$94.55M | -$34.47M | -$28.81M | +418.7% |
| Working capital | $300.99M | $20.77M | $43.03M | $21.02M | +1,349.2% |
| Net tangible assets | $301.31M | -$94.55M | -$34.47M | -$28.81M | +418.7% |
| Shares issued | 25.30M | 22.44M | 22.44M | 22.44M | +12.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Depreciation & amortisation | $321.00K | $91.00K | $4.00K | $2.00K | +252.7% |
| Stock-based compensation | $4.19M | $3.16M | $295.00K | $431.00K | +32.6% |
| Change in working capital | -$13.65M | $3.31M | -$1.31M | $86.00K | -512.0% |
| Operating cash flow | -$35.21M | -$53.05M | -$12.09M | -$2.73M | +33.6% |
| Capital expenditure | -$52.00K | -$769.00K | -$25.00K | — | +93.2% |
| Investing cash flow | -$39.89M | $23.23M | -$28.01M | $123.00K | -271.7% |
| Financing cash flow | $302.56M | $38.31M | $33.68M | $22.96M | +689.7% |
| Free cash flow | -$35.26M | -$53.82M | -$12.12M | -$2.73M | +34.5% |
| End cash position | $250.94M | $23.48M | $14.98M | $21.40M | +968.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $44.15M | $14.64M | $8.48M | $2.42M | $2.42M | +201.4% |
| Selling, general & admin | $9.77M | $7.46M | $5.39M | $2.83M | $2.44M | +31.0% |
| Total operating expense | $53.91M | $22.10M | $13.87M | $5.25M | $4.86M | +143.9% |
| Operating income | -$53.91M | -$22.10M | -$13.87M | -$5.25M | -$4.86M | -143.9% |
| Net interest income | $2.97M | $2.85M | $2.80M | $707.00K | $177.00K | +4.4% |
| Pre-tax income | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -170.8% |
| Tax provision | $0 | $0 | $1.00K | $0 | $0 | — |
| Net income | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -170.8% |
| Net income to common | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -170.8% |
| Basic EPS | -1.71 | -0.67 | -0.45 | -0.61 | -0.22 | -155.2% |
| Diluted EPS | -1.71 | -0.67 | -0.45 | -0.61 | -0.22 | -155.2% |
| EBIT | -$53.91M | -$22.10M | -$13.87M | -$5.25M | -$4.86M | -143.9% |
| EBITDA | -$53.82M | -$22.02M | -$13.79M | -$5.17M | -$4.78M | -144.4% |
| Basic shares | 30.14M | 28.24M | 25.41M | 5.81M | 22.44M | +6.7% |
| Diluted shares | 30.14M | 28.24M | 25.41M | 5.81M | 22.44M | +6.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $283.11M | $320.68M | $250.17M | $269.74M | $14.22M | -11.7% |
| Cash & short-term investments | $327.79M | $365.64M | $295.21M | $314.48M | $14.22M | -10.4% |
| Total current assets | $355.30M | $389.07M | $308.43M | $316.40M | $14.78M | -8.7% |
| Property, plant & equipment | $5.61M | $3.63M | $3.73M | $3.83M | $3.96M | +54.4% |
| Total assets | $361.69M | $393.48M | $312.93M | $320.75M | $19.25M | -8.1% |
| Total current liabilities | $23.56M | $10.91M | $7.44M | $6.65M | $3.91M | +116.1% |
| Total debt | $5.22M | $3.47M | $3.57M | $3.67M | $3.76M | +50.3% |
| Total liabilities | $29.34M | $14.79M | $11.62M | $10.53M | $123.12M | +98.4% |
| Retained earnings | -$200.19M | -$148.58M | -$129.53M | -$118.06M | -$114.50M | -34.7% |
| Shareholder equity | $332.35M | $378.69M | $301.31M | $310.22M | -$103.87M | -12.2% |
| Working capital | $331.74M | $378.17M | $300.99M | $309.75M | $10.88M | -12.3% |
| Net tangible assets | $332.35M | $378.69M | $301.31M | $310.22M | -$103.87M | -12.2% |
| Shares issued | 28.68M | 28.67M | 25.30M | 25.30M | 22.44M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | — | -170.8% |
| Depreciation & amortisation | $97.00K | $82.00K | $85.00K | $81.00K | $76.00K | — | +18.3% |
| Stock-based compensation | $4.90M | $2.57M | $2.34M | $881.00K | $335.00K | — | +91.0% |
| Change in working capital | $8.29M | -$6.75M | -$9.53M | -$97.00K | -$1.25M | — | +222.8% |
| Operating cash flow | -$37.63M | -$23.29M | -$18.10M | -$3.37M | -$5.60M | — | -61.6% |
| Capital expenditure | -$363.00K | -$32.00K | -$40.00K | — | — | -$21.00K | -1,034.4% |
| Investing cash flow | $89.00K | -$32.00K | -$40.00K | -$44.84M | $9.00K | — | +378.1% |
| Financing cash flow | -$19.00K | $93.83M | -$1.17M | $303.73M | $0 | — | -100.0% |
| Free cash flow | -$37.99M | -$23.32M | -$18.14M | -$3.37M | -$5.59M | — | -62.9% |
| End cash position | $283.89M | $321.45M | $250.94M | $270.26M | $14.73M | — | -11.7% |
Options analytics
Put / call volume
0.87
Call-heavy session
Put / call open interest
1.49
Positioning, not flow
Max pain
40.00
+16.8% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
82
Contracts, this expiry
Put volume
71
Contracts, this expiry
Heaviest call OI
45.00
52 contracts
Heaviest put OI
40.00
115 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.80 | -1.71 | -114.2% |
| Mar 2026 | -0.67 | — | — |
| Dec 2025 | -0.32 | -0.45 | -42.1% |
| Sep 2025 | -0.28 | -0.61 | -117.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.58 | 7 | $0 | 0.0% |
| Next quarter | -1.58 | 7 | $0 | 0.0% |
| Current year | -5.58 | 8 | $0 | 0.0% |
| Next year | -5.17 | 8 | $0 | 0.0% |
Analyst targets & ownership
Mean target$57.30
High target$80.00
Low target$35.00
Implied upside67.25%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders0.24%
Held by institutions102.44%
Institutions holding171
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.10
-7.66% from price
SMA 20
40.52
-15.44% from price
SMA 50
43.85
-21.87% from price
SMA 100
37.20
-7.90% from price
SMA 200
31.05
+10.33% from price
EMA 12
37.95
-9.73% from price
EMA 26
40.47
-15.35% from price
EMA 50
40.80
-16.04% from price
RSI (14)
26.2
Oversold
MACD (12,26,9)
-2.52
Hist -0.69
ATR (14)
1.91
5.57% of price
Realised vol 30D
44.1%
Annualised
Bollinger upper
48.07
20, 2σ
Bollinger lower
32.96
20, 2σ
50 / 200 cross
Golden
43.85 vs 31.05
Trend bias
Above 200
+10.33%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.50
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
44.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.8%
Peak to trough
Max drawdown 5Y
-30.8%
Peak to trough
ATR 14
1.91
5.57% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
5.62M
Prior 5.16M
Change vs prior
+8.9%
Shorts adding
% of float
20.49%
Heavily shorted
% of shares out
17.41%
Against total outstanding
Days to cover
21.0
Crowded exit
Float
26.46M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Guggenheim | INITIATED | — | Buy |
| Oct 5, 26 | Roth Capital | DOWNGRADE | Buy | Neutral |
| Oct 2, 26 | Needham | INITIATED | — | Buy |
| Aug 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 26 | BMO Capital | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 21, 26 | BMO Capital | INITIATED | — | Outperform |
| Jul 7, 26 | Wolfe Research | INITIATED | — | Outperform |
| Apr 27, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Apr 10, 26 | Craig-Hallum | INITIATED | — | Buy |
| Mar 27, 26 | Stifel | MAINTAINED | Buy | Buy |
| Dec 11, 25 | Stifel | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Post-effective amendment to a registration statement that is not immediately effective upon filing
POS AM · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-15
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-12
Annual Report to Shareholders
ARS · 2026-04-23
Headlines
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
GlobeNewswire · 1d ago
Guggenheim Initiates LB Pharmaceuticals at Buy With $80 Price Target
MT Newswires · 1d ago
Roth Capital Downgrades LB Pharmaceuticals to Neutral From Buy, Price Target is $37
MT Newswires · 2d ago
Needham Initiates LB Pharmaceuticals at Buy With $68 Price Target
MT Newswires · 5d ago
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
GlobeNewswire · 22d ago
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
Investor's Business Daily · 28d ago
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment
Simply Wall St. · 33d ago
LB Pharmaceuticals to Participate in Upcoming September Investor Events
GlobeNewswire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.